var data={"title":"Imiglucerase (glucocerebrosidase): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Imiglucerase (glucocerebrosidase): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6358?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=imiglucerase-glucocerebrosidase-patient-drug-information\" class=\"drug drug_patient\">see &quot;Imiglucerase (glucocerebrosidase): Patient drug information&quot;</a> and <a href=\"topic.htm?path=imiglucerase-glucocerebrosidase-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Imiglucerase (glucocerebrosidase): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181997\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cerezyme</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181998\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cerezyme</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182016\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Enzyme</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181999\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Note:</b> Dose should be individualized. IV:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gaucher disease, type 1:</b> Initial range: 2.5 units/kg 3 times weekly, up to 60 units/kg every 2 weeks. <b>Note:</b> Dosage adjustments are made based on assessment and therapeutic goals. Most benefits observed with doses of 30 to 60 units/kg every 2 weeks (Charrow 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gaucher disease, type 3 (Canadian labeling; not in US labeling):</b>Initial range: 2.5 units/kg 3 times weekly, up to 60 units/kg every 2 weeks. Doses up to 120 units/kg every 2 weeks have been safely administered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182008\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=imiglucerase-glucocerebrosidase-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Imiglucerase (glucocerebrosidase): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Note:</b> Dose should be individualized. IV:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gaucher disease, type 1: </b> Children and Adolescents: Limited data for children &lt;2 years: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: 30 to 60 units/kg/dose every 2 weeks; based on risk for complications (Andersson 2005; Baldellou 2004; Charrow 2004); failure to respond to treatment within 6 months may indicate the need for a higher dosage (Baldellou 2004); doses &gt;60 units/kg/dose are rarely needed (Charrow 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>High risk for complications:</i> Initial dose: 60 units/kg every 2 weeks. High risk is defined as one or more of the following: symptomatic disease including manifestations of abdominal or bone pain, fatigue, exertional limitations, weakness, and cachexia; growth failure; evidence of skeletal involvement; platelet count &le;60,000 mm<sup>3</sup> and/or documented abnormal bleeding episode(s); Hgb &ge;2 g/dL below lower limit for age and sex; impaired quality of life (Andersson 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance: Limited data available. Assess calculated dose and patient growth (weight) frequently to maintain consistent dosage per kg body weight (Baldellou 2004). The appropriate dose to prevent long-term complications in pediatric patients is unknown; after therapeutic goals achieved, any dose reduction should be considered with extreme caution and at intervals no more frequent than every 6 months; minimum dose: 30 units/kg/dose every 2 weeks (Andersson 2005; Baldellou 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gaucher disease, type 3 (Canadian labeling; not in US labeling):</b> Children &ge;2 years and Adolescents: Limited data for children &lt;2 years: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182000\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21026792\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21026793\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181982\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cerezyme: 400 units (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181970\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181984\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Infuse over 1 to 2 hours; may filter diluted solution  through an in-line, low protein-binding 0.2-micron filter during administration. The Canadian labeling recommends a maximum infusion rate of 1 unit/kg/minute. Infusion times &lt;1 hour are not recommended (Martins 2009). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181983\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;margin-left:0em;\">\n      <b>Gaucher disease:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>U.S. labeling:</i> Long-term enzyme replacement therapy for patients with type 1 Gaucher disease that results in at least one of the following: anemia, bone disease, hepatomegaly or splenomegaly, and thrombocytopenia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i>  Long-term enzyme replacement therapy for patients with type 1 Gaucher disease or patients with type 3 Gaucher disease who display non-neurological manifestations (anemia, bone disease, hepatomegaly or splenomegaly, and thrombocytopenia) of the disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182021\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cerezyme may be confused with Cerebyx, Ceredase</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181977\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Tachycardia (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Chills (&lt;2%), dizziness (&lt;2%), fatigue (&lt;2%), headache (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (&lt;2%), skin rash (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal distress (&lt;2%), diarrhea (&lt;2%), nausea (&lt;2%), vomiting (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction (7%; symptoms may include angioedema, chest discomfort, cough, cyanosis, dyspnea, flushing, hypotension, paresthesia, pruritus, urticaria)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylactoid reaction; burning sensation at injection site, cyanosis, peripheral edema, pneumonia, pulmonary hypertension, rigors, sterile abscess at injection site, swelling at injection site</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181987\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>U.S. labeling:</i> There are no known contraindications in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Severe hypersensitivity to imiglucerase or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181974\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylactic reactions: Have been reported (&lt;1%). Most patients have continued treatment with pretreatment (antihistamines and/or corticosteroids) and a slower rate of infusion. Discontinue immediately for severe reactions and initiate appropriate medical treatment. Use caution in patients with previous hypersensitivity to, previously treated with, or have developed antibodies to alglucerase. Canadian labeling contraindicates use in patients with severe hypersensitivity to imiglucerase.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Antibody formation: Development of IgG antibodies has been reported in ~15% of patients and has been observed within 6 months from the onset of therapy; antibody formation is rare after 12 months of therapy; may increase risk of hypersensitivity reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pulmonary hypertension/pneumonia: Has been observed during treatment; causal relationship has not been established as this is a complication of Gaucher disease. Afebrile patients with respiratory symptoms should be assessed for pulmonary hypertension.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens).  Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson, 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Experienced health care provider: Should be administered under the supervision of a health care provider experienced in treatment of Gaucher disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Registry: A registry has been established and all patients with Gaucher disease, and physicians who treat Gaucher disease are encouraged to participate. Information on the International Collaborative Gaucher Group (ICGG) Gaucher Registry may be obtained at https://www.registrynxt.com, or by calling 1-800-745-4447 (ext.15500). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299510\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6220960\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8981&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181979\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181989\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted; however, imiglucerase has been used safely during pregnancy based on available data (Sherer, 2003; Zimran, 2009). Doses of imiglucerase should be based on prepregnancy weight and adjusted as clinically indicated (Granovsky-Grisaru,  2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14722459\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if imiglucerase is excreted in breast milk. The manufacturer recommends that caution be exercised when administering imiglucerase to nursing women. A case report described a small amount of imiglucerase excreted into breast milk. The maximum amount of enzyme activity was obtained in the first milk at the end of the imiglucerase infusion; enzyme activity rapidly declined to preinfusion levels (Sekijima, 2010).  Enzyme ingested by a nursing infant would likely degrade in their digestive system (Zimran, 2009). The benefits of nursing to the infant should be weighed against the potential for additional bone loss in the mother (Granovsky-Grisaru, 2011; Zimran, 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181980\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC, platelets, liver function tests, IgG antibody formation periodically during the first year of treatment (Canadian labeling recommends antibody testing approximately every 3 months during the first year and at ~18 months), chitotriosidase, angiotensin-converting enzyme (ACE), acid phosphatase (AP), iron, iron-binding capacity, ferritin, vitamin B<sub>12</sub>; MRI or CT scan (liver and spleen volume), skeletal x-rays, DXA;  pulmonary function tests; ECG/echocardiography; growth in pediatric patients </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181973\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Imiglucerase is an analogue of glucocerebrosidase; it is produced by recombinant DNA technology using mammalian cell culture. Glucocerebrosidase is an enzyme deficient in Gaucher's disease. It is needed to catalyze the hydrolysis of glucocerebroside to glucose and ceramide.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181986\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Significant improvement in symptoms: Hepatosplenomegaly and hematologic abnormalities: Within 6 months; Improvement in bone mineralization: Noted at 80 to 104 weeks of therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 0.09 to 0.15 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 3.6 to 10.4 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Clearance: 9.8 to 20.3 mL/minute/kg </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323194\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cerezyme Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 unit (1): $1,903.20</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038657\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cerezyme (AT, AU, BB, BE, BG, BR, CH, CL, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, HR, HU, IE, IL, IT, JO, KR, LB, LT, LU, LV, MT, MY, NL, NO, NZ, PL, PT, RO, RU, SE, SG, SK, TH, TR, TW);</li>\n      <li>Cerezyzme (SI);</li>\n      <li>Tserezym (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imiglucerase-glucocerebrosidase-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Andersson HC, Charrow J, Kaplan P, et al. Individualization of long-term enzyme replacement therapy for Gaucher disease. <i>Genet Med</i>. 2005;7(2):105-110.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imiglucerase-glucocerebrosidase-drug-information/abstract-text/15714077/pubmed\" target=\"_blank\" id=\"15714077\">15714077</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baldellou A, Andria G, Campbell PE, et al, &quot;Paediatric Non-Neuronopathic Gaucher Disease: Recommendations for Treatment and Monitoring,&quot; <i>Eur J Pediatr</i>, 2004, 163(2):67-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imiglucerase-glucocerebrosidase-drug-information/abstract-text/14677062/pubmed\" target=\"_blank\" id=\"14677062\">14677062</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imiglucerase-glucocerebrosidase-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cerezyme (imiglucerase) [prescribing information]. Cambridge, MA: Genzyme Corporation; May 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cerezyme (imiglucerase) [product monograph]. Mississauga, Ontario, Canada; Genzyme Canada; April 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Charrow J, Andersson HC, Kaplan P, et al, &quot;Enzyme Replacement Therapy and Monitoring for Children With Type 1 Gaucher Disease: Consensus Recommendations,&quot; <i>J Pediatr</i>, 2004, 144(1):112-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imiglucerase-glucocerebrosidase-drug-information/abstract-text/14722528/pubmed\" target=\"_blank\" id=\"14722528\">14722528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Granovsky-Grisaru S, Belmatoug N, vom Dahl S, et al, &ldquo;The Management of Pregnancy in Gaucher Disease,&rdquo; <i>Eur J Obstet Gynecol Reprod Biol</i>, 2011, 156(1): 3-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imiglucerase-glucocerebrosidase-drug-information/abstract-text/21269752/pubmed\" target=\"_blank\" id=\"21269752\">21269752</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imiglucerase-glucocerebrosidase-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jmoudiak M and Futerman AH, &quot;Gaucher Disease: Pathological Mechanisms and Modern Management,&quot; <i>Br J Haematol</i>, 2005, 129(2):178-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imiglucerase-glucocerebrosidase-drug-information/abstract-text/15813845/pubmed\" target=\"_blank\" id=\"15813845\">15813845</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imiglucerase-glucocerebrosidase-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martins AM, Valadares ER, Porta G, et al, &ldquo;Recommendations on Diagnosis, Treatment, and Monitoring for Gaucher Disease,&rdquo; <i>J Pediatr</i>, 2009, 155(4 Suppl):10-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imiglucerase-glucocerebrosidase-drug-information/abstract-text/19765407/pubmed\" target=\"_blank\" id=\"19765407\">19765407</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pastores GM, Weinreb NJ, Aerts H, et al, &quot;Therapeutic Goals in the Treatment of Gaucher Disease,&quot; <i>Semin Hematol</i>, 2004, 41(4 Suppl 5):4-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imiglucerase-glucocerebrosidase-drug-information/abstract-text/15468045/pubmed\" target=\"_blank\" id=\"15468045\">15468045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sekijima Y, Ohashi T, Ohira S, et al, &ldquo;Successful Pregnancy and Lactation Outcome in a Patient With Gaucher Disease Receiving Enzyme Replacement Therapy, and the Subsequent Distribution and Excretion of Imiglucerase in Human Breast Milk,&rdquo; <i>Clin Ther</i>, 2010, 32(12):2048-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imiglucerase-glucocerebrosidase-drug-information/abstract-text/21118740/pubmed\" target=\"_blank\" id=\"21118740\">21118740</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imiglucerase-glucocerebrosidase-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sherer Y, Dulitzki M, Levy Y, et al, &ldquo;Successful Pregnancy Outcome in a Patient With Gaucher&rsquo;s Disease and Antiphospholipid Syndrome,&rdquo; <i>Ann Hematol</i>, 2002, 81(3):161-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imiglucerase-glucocerebrosidase-drug-information/abstract-text/11904743/pubmed\" target=\"_blank\" id=\"11904743\">11904743</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weinreb NJ, Aggio MC, Andersson HC, et al, &quot;Gaucher Disease Type 1: Revised Recommendations on Evaluations and Monitoring for Adult Patients,&quot; <i>Semin Hematol</i>, 2004, 41(4 Suppl 5):15-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imiglucerase-glucocerebrosidase-drug-information/abstract-text/15468046/pubmed\" target=\"_blank\" id=\"15468046\">15468046</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zimran A, Morris E, Mengel E, et al, &ldquo;The Female Gaucher Patient: The Impact of Enzyme Replacement Therapy Around Key Reproductive Events (Menstruation, Pregnancy and Menopause),&rdquo; <i>Blood Cells Mol Dis</i>, 2009, 43(3):264-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imiglucerase-glucocerebrosidase-drug-information/abstract-text/19502088/pubmed\" target=\"_blank\" id=\"19502088\">19502088</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8981 Version 90.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F181997\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F181998\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F182016\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F181999\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F182008\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F182000\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F21026792\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F21026793\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F181982\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F181970\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F181984\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F181983\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F182021\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F181977\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F181987\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F181974\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299510\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6220960\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F181979\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F181989\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F14722459\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F181980\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F181973\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F181986\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323194\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038657\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8981|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=imiglucerase-glucocerebrosidase-patient-drug-information\" class=\"drug drug_patient\">Imiglucerase (glucocerebrosidase): Patient drug information</a></li><li><a href=\"topic.htm?path=imiglucerase-glucocerebrosidase-pediatric-drug-information\" class=\"drug drug_pediatric\">Imiglucerase (glucocerebrosidase): Pediatric drug information</a></li></ul></div></div>","javascript":null}